loading...| Preferred Name |
lapatinib ditosylate |
|
| Synonyms |
GW2016 |
|
| Definitions |
The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66878" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66878" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000269659 |
|
| altLabel |
GW2016 GSK572016 Lapatinib GW-572016 Tykerb |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000371599 http://purl.bioontology.org/ontology/PDQ/CDR0000371642 |
|
| cui |
C1173538 C1506770 C1721362 C1708163 C1384663 C1504917 |
|
| DATE FIRST PUBLISHED |
2002-12-21 |
|
| Date last modified |
2016-04-27 |
|
| definition |
The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66878" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66878" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C66878 |
|
| notation |
CDR0000269659 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
lapatinib ditosylate |
|
| tui |
T109 T121 |